This Boston Based Startup is Applying Machine Learning-Anchored Computation to Enhance Drug Discovery and Development

Valo Health is a drug development company headquartered in Boston, Massachusetts, the United States, which uses human-centric data and machine learning to strengthen and boost the process of drug discovery and its development to promote intelligent health. The Opal Computational Platform by Valo Health utilizes the available clinical data and identifies the different molecules present to better the therapy results. This ensures that the procedure of drug discovery is an end-to-end process and can be used for an entire plethora of diseases. In the recent Series B funding rounds, this organization managed to add another $100 million in its funding, taking the total funding received in this round to $300 million. This funding will be primarily utilized for R&D to further improve technology and expand the drug development program.

This organization was formed in 2019 by David Berry under Flagship Pioneering, a Cambridge-based mega-giant already having companies like Moderna and Indigo Ag in its ambit. Valo Health’s main aim is to use machine learning in a manner wherein previously unknown molecules’ associations can be identified and brought to light. The focus here is unlimited, and Valo Health claims that their products could be highly disruptive to the industry and bring in significant value so as to equip the people with better and enhanced treatment alternatives.

The entire process of drug discovery and development is being re-imagined by Valo Health. By using artificial intelligence and machine learning, the process’s cost and time have been potentially cut in half. The technology at this organization blends in an enormous amount of human data with machine learning computation to allow itself to go from simply making molecules to then testing them in mere months. This allows medical chemistry optimization on a large scale.

Valo Health was formerly known as Integral Health, and it was launched after acquiring two firms, Forma Therapeutics, and Numerate which not only provided it with a sound capital from discoveries but also gave the essential asset in the form of engineers who had already created a base of 30,000 models and around 70 trillion molecules. The company unites human intelligence and machine intelligence to accelerate the entire process. It claims that it has been able to manufacture the first closed-loop, human-centric, activity learning, and end-to-end integrated drug discovery and development engine.

The company builds off the experience and products available from the other firms in the market and tries to look at it from a different perspective altogether, keeping an eye out for new opportunities to improve the same or even extend it further up a notch. The company, as of now, is focusing on advancing new medicines, refining its discovery and developmental engine, and coming up with new programs.

Source Link:

 | Website

Amreen Bawa is a consulting intern at MarktechPost. Along with pursuing BA Hons in Social Sciences from Panjab University, Chandigarh, she is also a keen learner and writer, having special interest in the application and scope of artificial intelligence in various facets of life.

🐝 Join the Fastest Growing AI Research Newsletter Read by Researchers from Google + NVIDIA + Meta + Stanford + MIT + Microsoft and many others...